Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Parr

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Urologia Internationalis|March 22, 2016
Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic CatheterisationDebashis Sarkar, Kingsley Ekwueme, Nigel Parr
Journal of Surgical Case Reports|June 26, 2014
The twisted diversion: a paralyzing complicationKenneth Hiew, Richard Glendinning, Nigel Parr, et al.
Bioorganic & Medicinal Chemistry Letters|February 4, 2006
Pyridone derivatives as potent and selective VLA-4 integrin antagonistsJason Witherington, Vincent Bordas, Alessandra Gaiba, et al.
BJU International|December 9, 2015
Dynamic sentinel lymph node biopsy for penile cancer: a comparison between 1- and 2-day protocolsPanagiotis Dimopoulos, Panagiotis Christopoulos, Sam Shilito, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2020
Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'David J Hirst, Martin Brandt, Gordon Bruton, et al.
Journal of Bone Oncology|September 30, 2020
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert groupJanet E Brown, Catherine Handforth, Juliet E Compston, et al.
Plos One|September 7, 2013
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor modelsAnastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical ProgressionKatherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Cancer Research|November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapySarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Urologia Internationalis|March 22, 2016
Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic CatheterisationDebashis Sarkar, Kingsley Ekwueme, Nigel Parr
Journal of Surgical Case Reports|June 26, 2014
The twisted diversion: a paralyzing complicationKenneth Hiew, Richard Glendinning, Nigel Parr, et al.
Bioorganic & Medicinal Chemistry Letters|February 4, 2006
Pyridone derivatives as potent and selective VLA-4 integrin antagonistsJason Witherington, Vincent Bordas, Alessandra Gaiba, et al.
BJU International|December 9, 2015
Dynamic sentinel lymph node biopsy for penile cancer: a comparison between 1- and 2-day protocolsPanagiotis Dimopoulos, Panagiotis Christopoulos, Sam Shilito, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2020
Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'David J Hirst, Martin Brandt, Gordon Bruton, et al.
Journal of Bone Oncology|September 30, 2020
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert groupJanet E Brown, Catherine Handforth, Juliet E Compston, et al.
Plos One|September 7, 2013
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor modelsAnastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical ProgressionKatherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Cancer Research|November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapySarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
Pageof 1